1. Tuomilehto, J. The emerging global epidemic of type 1 diabetes. Curr Diab Rep 2013; 13(6): 795–804.
Google Scholar | Crossref | Medline2. Zheng, Y, Ley, SH, Hu, FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complication. Nat Rev Endocrinol 2018; 14(2): 88–98.
Google Scholar | Crossref | Medline3. Saeedi, P, Petersohn, I, Salpea, P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019; 157: 10784.
Google Scholar | Crossref4. Mazibuko-Mbeje, SE, Dludla, PV, Johnson, R, et al. Aspalathin, a natural product with the potential to reverse hepatic insulin resistance by improving energy metabolism and mitochondrial respiration. PLoS ONE 2019; 14(5): e0216172.
Google Scholar | Crossref | Medline5. Roberts, CK, Hevener, AL, Barnard, RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol 2013; 3(1): 1–58.
Google Scholar | Medline6. Rui, L. Energy metabolism in the liver. Compr Physiol 2014; 4(1): 177–197.
Google Scholar | Crossref | Medline7. Moore, MC, Coate, KC, Winnick, JJ, et al. Regulation of hepatic glucose uptake and storage in vivo. Adv Nutr 2012; 3(3): 286–294.
Google Scholar | Crossref | Medline8. Nakagawa, Y, Satoh, A, Yabe, S, et al. Hepatic CREB3L3 controls whole-body energy homeostasis and improves obesity and diabetes. Endocrinology 2014; 155(12): 4706–4719.
Google Scholar | Crossref | Medline9. Watt, MJ, Miotto, PM, De Nardo, W, et al. The Liver as an Endocrine Organ—Linking NAFLD and Insulin Resistance. Endocr Rev 2019; 40(5): 1367–1393.
Google Scholar | Crossref | Medline10. Kraegen, EW, Clark, PW, Jenkins, AB, et al. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 1991; 40(11): 1397–1403.
Google Scholar | Crossref | Medline11. Turner, N, Kowalski, GM, Leslie, SJ, et al. Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding. Diabetologia 2013; 56(7): 1638–1648.
Google Scholar | Crossref | Medline12. Inoki, K, Kim, J, Guan, KL. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol 2012; 52: 381–400.
Google Scholar | Crossref | Medline13. Kimball, SR, Siegfried, BA, Jefferson, LS. Glucagon represses signaling through the mammalian target of rapamycin in rat liver by activating AMP-activated protein kinase. J Biol Chem 2004; 279(52): 54103–54109.
Google Scholar | Crossref | Medline14. Le Bacquer, O, Petroulakis, E, Paglialunga, S, et al. Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest 2007; 117(2): 387–396.
Google Scholar | Crossref | Medline15. Um, SH, Frigerio, F, Watanabe, M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004; 431(7005): 200–205.
Google Scholar | Crossref | Medline16. Saha, AK, Avilucea, PR, Ye, JM, et al. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun 2004; 314(2): 580–585.
Google Scholar | Crossref | Medline17. Shah, P, Mudaliar, S. Pioglitazone: side effect and safety profile. Expert Opin Drug Saf 2010; 9(2): 347–354.
Google Scholar | Crossref | Medline18. Shadid, S, Jensen, MD. Angioneurotic edema as a side effect of pioglitazone. Diabetes Care 2002; 25(2): 405.
Google Scholar | Crossref | Medline19. Liang, F, Koya, D. Acupuncture: is it effective for treatment of insulin resistance. Diabetes Obes Metab 2010; 12(7): 555–569.
Google Scholar | Crossref | Medline20. Litscher, G. The application of bioengineering of acupuncture to the treatment of diabetes, insulin resistance and obesity. Diabetes Obes Metab 2010; 12(7): 553–554.
Google Scholar | Crossref | Medline21. Cabioglu, MT, Gündogan, N, Ergene, N. The efficacy of electroacupuncture therapy for weight loss changes plasma lipoprotein A, apolipoprotein A and apolipoprotein B levels in obese women. Am J Chin Med 2008; 36(6): 1029–1039.
Google Scholar | Crossref | Medline22. Cabioğlu, MT, Ergene, N. Changes in levels of serum insulin, C-Peptide and glucose after electroacupuncture and diet therapy in obese women. Am J Chin Med 2006; 34(3): 367–376.
Google Scholar | Crossref | Medline23. Lin, RT, Tzeng, CY, Lee, YC, et al. Acute effect of electroacupuncture at the Zusanli acupoints on decreasing insulin resistance as shown by lowering plasma free fatty acid levels in steroid-background male rats. BMC Complement Altern Med 2009; 9: 26.
Google Scholar | Crossref | Medline24. Cao, BY, Li, R, Tian, HH, et al. PI3K-GLUT4 signal pathway associated with effects of EX-B3 electroacupuncture on hyperglycemia and insulin resistance of T2DM rats. Evid Based Complement Alternat Med 2016; 2016: 7914387.
Google Scholar | Crossref | Medline25. Tominaga, A, Ishizaki, N, Naruse, Y, et al. Repeated application of low-frequency electroacupuncture improves high-fructose diet-induced insulin resistance in rats. Acupunct Med 2011; 29(4): 276–283.
Google Scholar | SAGE Journals26. Srinivasan, K, Ramarao, P. Animal models in type 2 diabetes research: an overview. Indian J Med Res 2007; 125(3): 451–472.
Google Scholar | Medline27. Haeusler, RA, Accili, D. The double life of IRS. Cell Metab 2008; 8(1): 7–9.
Google Scholar | Crossref | Medline28. Kahn, BB, Flier, JS. Obesity and insulin resistance. J Clin Invest 2000; 106(4): 473–481.
Google Scholar | Crossref | Medline29. Savage, DB, Petersen, KF, Shulman, GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 2007; 87(2): 507–520.
Google Scholar | Crossref | Medline30. Unger, RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003; 144(12): 5159–5165.
Google Scholar | Crossref | Medline31. Meex, RCR, Watt, MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol 2017; 13(9): 509–520.
Google Scholar | Crossref | Medline32. Stefan, N, Fritsche, A, Schick, F, et al. Phenotypes of prediabetes and stratification of cardiometabolic risk. Lancet Diabetes Endocrinol 2016; 4(9): 789–798.
Google Scholar | Crossref | Medline33. Inoki, K, Li, Y, Xu, T, et al. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003; 17(15): 1829–1834.
Google Scholar | Crossref | Medline